Glaukos Receives FDA Approval of NDA Supplement for Re-Administration of iDose TR

ALISO VIEJO, Calif.—Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced that the U.S. Food and Drug Administration (FDA) has approved an NDA (new drug application) labeling supplement allowing for re-administration of iDose TR using a repeat treatment protocol. The FDA approval is in response to Glaukos’ 2025 NDA labeling supplement application, the company advised. iDose TR was originally approved by the FDA for single dose administration per eye in December 2023.